Alzheimer’s medical drink fails primary endpoint, but shows promise for slowing cognitive decline

Written by Lauren Pulling, Editor

Results from the European LipiDiDiet clinical trial investigating the effectiveness of a medical drink proposed to benefit mild Alzheimer’s disease (AD) dementia were today published online in The Lancet Neurology. While primary endpoints were not met, the drink did show a stabilization in cognitive performance and reduced brain shrinkage. In the 24-month randomized, controlled, double-blind trial, 311 participants with prodromal AD were assigned to either take a daily 125 ml dose of the active drink Souvenaid, containing Fortasyn Connect, or a non-active control drink. The primary endpoint was a change in neuropsychological test battery (NTB) score. The 24-month results published...

To view this content, please register now for access

It's completely free